The Drug Regulatory Authority of Pakistan (DRAP) has issued manufacturing licenses to local manufacturers for a new low-cost cardiac medicine to facilitate patients. This medicine will be available at half the rate compared to imported medicines, providing significant relief to heart patients across the country.
DRAP Approves Manufacturing of New Heart Medicine
Published: 2026-07-14 01:59:16
By: Editorial Desk
Views: 33
Text Size:
Express your reaction to this article:
Latest News
-
Drug sale licences in Pakistan officially cost Rs5,000, but industry sources claim applicants often face expenses exceeding Rs250,000. Concerns over ghost pharmacists and weak enforcement continue to grow.
2026-07-27 19:56:34
-
DRAP registration delays affecting pharmaceutical exports in Pakistan
2026-07-27 18:37:40
-
Importance of Writing Medical Research Papers - By Dr. Nadia Ali
2026-07-14 01:59:16
-
Climate Change and New Diseases: A Wake-Up Call - By Prof. Ayesha Khan
2026-07-14 01:59:16
-
Promotion of Alternative Medicines and Code of Conduct - By Dr. Rizwan Qureshi
2026-07-14 01:59:16
Comments & Discussion (0)
Leave a Comment